Colorectal Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CLR109 MIFTS: 53	Colorectal Adenocarcinoma Categories: Cancer diseases, Gastrointestinal diseases
Genes Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Colorectal Adenocarcinoma

MalaCards integrated aliases for Colorectal Adenocarcinoma:

Name: Colorectal Adenocarcinoma ¹² ¹⁵

Adenocarcinoma of Large Intestine ⁷³

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0050861

UMLS ⁷³ C1319315

Sources

Summaries for Colorectal Adenocarcinoma

Disease Ontology : ¹² A colorectal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Colorectal Adenocarcinoma, also known as adenocarcinoma of large intestine, is related to mucinous bronchioloalveolar adenocarcinoma and gastrointestinal stromal tumor. An important gene associated with Colorectal Adenocarcinoma is FABP6 (Fatty Acid Binding Protein 6), and among its related pathways/superpathways are Developmental Biology and fMLP Pathway. The drugs Iron and Ferric Compounds have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and lung, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Colorectal Adenocarcinoma

Diseases related to Colorectal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 296)

#	Related Disease	Score	Top Affiliating Genes
1	mucinous bronchioloalveolar adenocarcinoma	30.7	CDX2 KRT20 KRT7
2	gastrointestinal stromal tumor	30.4	BRAF EGFR KRAS TP53
3	villous adenoma	30.4	BRAF CDX2 KRAS KRT20
4	colorectal adenoma	30.2	CTNNB1 HRAS KRAS MLH1 MSH2 TP53
5	chordoma	30.1	CDH1 EGFR KRT7 TP53
6	adenocarcinoma	30.0	BRAF CDH1 CTNNB1 EGFR HRAS KRAS
7	suppression of tumorigenicity 12	29.7	BRAF CTNNB1 HRAS TP53
8	adenoma	29.2	BRAF CTNNB1 KRAS MLH1 MSH2 TP53
9	bladder adenocarcinoma	29.2	CDX2 CTNNB1 HRAS KRT20 KRT7
10	renal cell carcinoma, nonpapillary	28.8	CDH1 EGFR KRT20 KRT7
11	small intestinal adenocarcinoma	28.6	BRAF CDX2 CTNNB1 EGFR KRAS MUC2
12	squamous cell carcinoma	28.5	BRAF CDH1 CTNNB1 EGFR HRAS KRAS
13	mucinous adenocarcinoma	28.5	CDX2 EGFR KRAS KRT20 KRT7 MLH1
14	familial adenomatous polyposis	28.4	CDH1 CTNNB1 KRAS MLH1 MSH2 TP53
15	lynch syndrome	28.1	BRAF CTNNB1 KRAS MLH1 MSH2 MUC2
16	esophageal cancer	27.6	CDH1 CDX2 CEACAM5 CTNNB1 EGFR HRAS
17	hepatocellular carcinoma	27.6	CDH1 CEACAM5 CTNNB1 EGFR HRAS KRAS
18	lung cancer susceptibility 3	26.6	BRAF CDH1 CDX2 CEACAM5 CTNNB1 EGFR
19	gastric adenocarcinoma	25.2	BRAF CDH1 CDX2 CEACAM5 CTNNB1 EGFR
20	colorectal cancer	24.5	AURKA BRAF CDH1 CDX2 CEACAM5 CTNNB1
21	nevus of ota	11.0	BRAF TP53
22	rare adenocarcinoma of the breast	11.0	KRAS TP53
23	ovary neuroendocrine neoplasm	10.9	CDX2 KRT7
24	cystic basal cell carcinoma	10.9	KRT20 KRT7
25	hyperplastic polyposis syndrome	10.9	BRAF KRAS TP53
26	brain ependymoma	10.9	EGFR TP53
27	mature teratoma	10.9	BRAF KRAS TP53
28	mucoepidermoid esophageal carcinoma	10.9	CEACAM5 TP53
29	eccrine sweat gland neoplasm	10.9	KRT20 KRT7 TP53
30	seminal vesicle adenocarcinoma	10.9	KRT20 KRT7
31	transverse colon cancer	10.8	KRT20 KRT7
32	papillary serous adenocarcinoma	10.8	KRT20 KRT7 TP53
33	ovarian large-cell neuroendocrine carcinoma	10.8	KRT20 KRT7
34	glycogen-rich clear cell breast carcinoma	10.8	KRT20 KRT7 TP53
35	anal paget's disease	10.8	CDX2 CEACAM5
36	cutaneous mucoepidermoid carcinoma	10.8	CEACAM5 KRT7
37	anal gland adenocarcinoma	10.8	CEACAM5 KRT7
38	vaginal benign neoplasm	10.8	CDX2 KRT20 KRT7
39	appendix adenocarcinoma	10.8	CDX2 KRT20 KRT7
40	vaginal adenoma	10.8	CDX2 KRT20 KRT7
41	vaginal tubulovillous adenoma	10.8	CDX2 KRT20 KRT7
42	ovarian clear cell carcinoma	10.8	KRAS KRT7 TP53
43	glandular cystitis	10.8	CDX2 KRT20 KRT7
44	inverted papilloma	10.8	KRT20 KRT7 TP53
45	benign breast adenomyoepithelioma	10.8	EGFR KRT7
46	gallbladder squamous cell carcinoma	10.8	CEACAM5 TP53
47	jejunal adenocarcinoma	10.8	CDX2 KRT20 KRT7
48	sweat gland cancer	10.8	KRT20 KRT7 TP53
49	chronic cystitis	10.8	CDX2 KRT20 KRT7
50	eyelid neoplasm	10.8	KRT20 KRT7

Graphical network of the top 20 diseases related to Colorectal Adenocarcinoma:

Sources

Symptoms & Phenotypes for Colorectal Adenocarcinoma

GenomeRNAi Phenotypes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

²⁶ (show all 16)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-2	10.92	KRAS EGFR HRAS PIM2 AURKA BRAF
2	Decreased viability	GR00106-A-0	10.92	KRAS
3	Decreased viability	GR00173-A	10.92	CDK8
4	Decreased viability	GR00221-A-1	10.92	EGFR KRAS HRAS PIM2 CDH1 AURKA
5	Decreased viability	GR00221-A-2	10.92	KRAS HRAS AURKA CDK8
6	Decreased viability	GR00221-A-3	10.92	HRAS
7	Decreased viability	GR00221-A-4	10.92	EGFR AURKA CDK8 BRAF
8	Decreased viability	GR00231-A	10.92	AURKA
9	Decreased viability	GR00301-A	10.92	KRAS MSH2 PIM2 CDH1 CDK8 BRAF
10	Decreased viability	GR00381-A-1	10.92	KRAS BRAF
11	Decreased viability	GR00402-S-2	10.92	EGFR KRAS HRAS MSH2 PIM2 AURKA
12	Decreased cell migration	GR00055-A-1	9.97	HRAS PIM2 KRAS EGFR CDK8 BRAF
13	Decreased viability in esophageal squamous lineage	GR00235-A	9.9	FABP6 KRAS KRT7 MLH1 HRAS TP53
14	Decreased cella89culturea89derived Hepatitis C virus (HCVcc; Luca89Jc1) infection	GR00234-A-2	9.5	EGFR CDK8 BRAF
15	Increased cell migration	GR00055-A-3	9.43	EGFR KRAS HRAS AURKA CTNNB1 BRAF
16	Increased cell viability after pRB stimulation	GR00230-A-1	8.92	EGFR PIM2 AURKA CDK8

MGI Mouse Phenotypes related to Colorectal Adenocarcinoma:

⁴⁶ (show all 11)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.27	MSH2 MUC2 KRAS TP53 KRT7 MLH1
2	digestive/alimentary	MP:0005381	10.22	HRAS MSH2 MUC2 KRAS TP53 MLH1
3	homeostasis/metabolism	MP:0005376	10.22	HRAS MSH2 MUC2 KRAS TP53 KRT7
4	mortality/aging	MP:0010768	10.17	HRAS MSH2 MUC2 KRAS TP53 MLH1
5	endocrine/exocrine gland	MP:0005379	10.13	HRAS MUC2 KRAS TP53 MLH1 CTNNB1
6	embryo	MP:0005380	10.11	KRAS TP53 CDX2 AURKA CTNNB1 BRAF
7	neoplasm	MP:0002006	10.03	MSH2 MUC2 KRAS TP53 MLH1 HRAS
8	integument	MP:0010771	10.02	HRAS MSH2 KRAS TP53 MLH1 CTNNB1
9	no phenotypic analysis	MP:0003012	9.7	HRAS KRAS TP53 AURKA CTNNB1 CDH1
10	pigmentation	MP:0001186	9.35	KRAS TP53 CTNNB1 BRAF EGFR
11	renal/urinary system	MP:0005367	9.17	HRAS KRAS KRT7 TP53 CTNNB1 BRAF

Sources

Drugs & Therapeutics for Colorectal Adenocarcinoma

Drugs for Colorectal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Iron

Approved

Phase 4

7439-89-6

23925

Ferric Compounds

Phase 4

Hematinics

Phase 4,Phase 3,Phase 2,Phase 1

Hepcidins

Phase 4

Iron Supplement

Nutraceutical

Phase 4

Bevacizumab

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

216974-75-3

Capecitabine

Approved, Investigational

Phase 3,Phase 2,Phase 1

154361-50-9

60953

Oxaliplatin

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

61825-94-3

5310940 9887054 43805 6857599

Fluorouracil

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

51-21-8

3385

Levoleucovorin

Approved, Investigational

Phase 3,Phase 2,Phase 1

68538-85-2

Irinotecan

Approved, Investigational

Phase 2, Phase 3,Phase 1

97682-44-5, 100286-90-6

60838

Nicotine

Approved

Phase 3

54-11-5

942 89594

leucovorin

Approved, Nutraceutical

Phase 3,Phase 2,Phase 1,Not Applicable

58-05-9

143 6006

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2,Phase 1,Not Applicable

59-30-3

6037

Glutamic Acid

Approved, Nutraceutical

Phase 3

56-86-0

33032

Angiogenesis Inhibitors

Phase 3,Phase 2,Phase 1,Not Applicable

Angiogenesis Modulating Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Antimetabolites

Phase 3,Phase 2,Phase 1,Not Applicable

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1,Not Applicable

Antidotes

Phase 3,Phase 2,Phase 1,Not Applicable

Calcium, Dietary

Phase 3,Phase 2

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Protective Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Liver Extracts

Phase 3,Phase 2,Phase 1,Not Applicable

Pharmaceutical Solutions

Phase 3,Phase 2

Antibodies

Phase 3,Phase 2,Phase 1

Antibodies, Monoclonal

Phase 3,Phase 2,Phase 1

Immunoglobulins

Phase 3,Phase 2,Phase 1

Micronutrients

Phase 3,Phase 2,Phase 1,Not Applicable

Trace Elements

Phase 3,Phase 2,Phase 1,Not Applicable

Vitamin B Complex

Phase 3,Phase 2,Phase 1,Not Applicable

Vitamins

Phase 3,Phase 2,Phase 1,Not Applicable

Bone Density Conservation Agents

Phase 3,Phase 2

Endothelial Growth Factors

Phase 3,Phase 2

Immunoglobulin G

Phase 3,Phase 2

Mitogens

Phase 3,Phase 2,Phase 1

Formyltetrahydrofolates

Phase 3

Tetrahydrofolates

Phase 3

Mitomycins

Phase 2, Phase 3

Folate

Nutraceutical

Phase 3,Phase 2,Phase 1,Not Applicable

Vitamin B9

Nutraceutical

Phase 3,Phase 2,Phase 1,Not Applicable

Paclitaxel

Approved, Vet_approved

Phase 2,Phase 1

33069-62-4

36314

Everolimus

Approved

Phase 2,Phase 1

159351-69-6

6442177

Miconazole

Approved, Investigational, Vet_approved

Phase 2,Phase 1

22916-47-8

4189

Sirolimus

Approved, Investigational

Phase 2,Phase 1

53123-88-9

5284616 6436030 46835353

Celecoxib

Approved, Investigational

Phase 2

169590-42-5

2662

Gefitinib

Approved, Investigational

Phase 2

184475-35-2

123631

Cetuximab

Approved

Phase 2,Phase 1

205923-56-4

56842117 2333

Tegafur

Approved, Investigational

Phase 2

17902-23-7

5386

Azacitidine

Approved, Investigational

Phase 1, Phase 2

320-67-2

9444

Interventional clinical trials:

(show top 50) (show all 119)

#	Name	Status	NCT ID	Phase	Drugs
1	Intravenous Iron: Measuring Response in Anemic Surgical Patients	Completed	NCT02057471	Phase 4	Intravenous ferric carboxymaltose
2	IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia	Completed	NCT01701310	Phase 4	Ferric carboxymaltose;Ferrous Sulphate
3	Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases	Completed	NCT00265356	Phase 3
4	A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer	Completed	NCT00623805	Phase 3	Bevacizumab;Capecitabine;Oxaliplatin
5	Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM	Recruiting	NCT03125161	Phase 3	HAI;chemotherapy ± target therapy
6	Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer	Recruiting	NCT02997228	Phase 3	Atezolizumab;Fluorouracil;Leucovorin Calcium;Oxaliplatin
7	5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab	Recruiting	NCT03300609	Phase 3	Oxaliplatin;Leucovorin Calcium;Fluorouracil;Capecitabine
8	Perioperative Systemic Therapy and Surgery Versus Surgery Alone for Resectable Colorectal Peritoneal Metastases.	Recruiting	NCT02758951	Phase 2, Phase 3	Perioperative systemic therapy
9	A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)	Active, not recruiting	NCT02788279	Phase 3	Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody;Cobimetinib;Regorafenib
10	Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）	Active, not recruiting	NCT02390947	Phase 3	Famitinib;Placebo
11	Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma	Unknown status	NCT01552967	Phase 2	Capecitabine
12	Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .	Unknown status	NCT02788006	Phase 2	Regorafenib 160 mg
13	Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.	Unknown status	NCT01067053	Phase 2	bevacizumab, capecitabine, oxaliplatin
14	Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma	Unknown status	NCT00075556	Phase 2	capecitabine
15	Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer	Unknown status	NCT00544011	Phase 2	capecitabine;fluorouracil;irinotecan hydrochloride
16	Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer	Unknown status	NCT00104689	Phase 2	capecitabine;oxaliplatin
17	Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer	Unknown status	NCT00027833	Phase 2	FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
18	Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma	Completed	NCT00034190	Phase 2	S-8184 Paclitaxel Injectable Emulsion
19	Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)	Completed	NCT01900717	Phase 2	LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified;LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
20	Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma	Completed	NCT00168155	Phase 2	perioperative chemotherapy
21	Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.	Completed	NCT02181465	Phase 2
22	Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma	Completed	NCT00574171	Phase 2	lapatinib;Capecitabine
23	Efficacy and Safety of Simtuzumab With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma	Completed	NCT01479465	Phase 2	Simtuzumab;FOLFIRI;Placebo to match simtuzumab
24	DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma	Completed	NCT00080834	Phase 2	DJ-927
25	Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy	Completed	NCT00419159	Phase 2	Everolimus (RAD001)
26	Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus	Completed	NCT00597506	Phase 2	Bevacizumab;Everolimus
27	Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma	Completed	NCT00165217	Phase 2	Capecitabine;Thalidomide
28	Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas	Completed	NCT01730586	Phase 2	Abraxane
29	Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib	Completed	NCT00582660	Phase 2	Celecoxib;Placebo
30	Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer	Completed	NCT00003220	Phase 2	bryostatin 1
31	Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer	Completed	NCT00025350	Phase 2	gefitinib
32	Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone	Completed	NCT00890305	Phase 2	CT-011;FOLFOX
33	Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver	Completed	NCT00149396	Phase 1, Phase 2	NV1020
34	1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer	Completed	NCT01417494	Phase 2	Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen);Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab
35	Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer	Completed	NCT00123851	Phase 2	Tarceva (OSI-774);Capecitabine;Oxaliplatin
36	Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy	Completed	NCT01225744	Phase 2	Cetuximab;Irinotecan;Oxaliplatin;UFT
37	Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed	Completed	NCT00259844	Phase 2
38	Azacitidine and CAPOX in Metastatic Colorectal Cancer	Completed	NCT01193517	Phase 1, Phase 2	Azacitidine;Capecitabine;Oxaliplatin;Azacitidine MTD
39	Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases	Recruiting	NCT02185443	Phase 2
40	Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver	Recruiting	NCT03069950	Phase 2	Floxuridine (FUDR);Irinotecan (CPT-11);FLUOROURACIL;PANITUMUMAB;DEXAMETHASONE;Leucovorin
41	Trial of Liver Resection Versus No Surgery in Patients With Liver and Unresectable Pulmonary Metastases From Colorectal Cancer (Liver Resection With Unresectable Lung Nodules From Colorectal Adenocarcinoma - LUNA)	Recruiting	NCT02738606	Phase 2	Chemotherapy
42	PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC	Recruiting	NCT03442569	Phase 2	Panitumumab;Nivolumab;Ipilimumab
43	Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer	Recruiting	NCT01053013	Phase 2
44	A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors	Recruiting	NCT02599324	Phase 1, Phase 2	ibrutinib;everolimus;docetaxel;paclitaxel;cetuximab
45	Regorafenib in Metastatic Colorectal Cancer	Recruiting	NCT02466009	Phase 2	Regorafenib
46	Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors	Recruiting	NCT01876511	Phase 2	MK-3475;MK-3475
47	A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer	Recruiting	NCT03206073	Phase 1, Phase 2
48	TAS102 in Combination With NAL-IRI in Advanced GI Cancers	Recruiting	NCT03368963	Phase 1, Phase 2	Nanoliposomal Irinotecan;Trifluridine and Tipiracil Hydrochloride
49	Tucatinib (ONT-380) and Trastuzumab in Treating Patients With HER2+ Metastatic Colorectal Cancer	Recruiting	NCT03043313	Phase 2	Tucatinib
50	Panitumumab in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer	Recruiting	NCT03087071	Phase 2	Panitumumab;Trametinib

Search NIH Clinical Center for Colorectal Adenocarcinoma

Sources

Genetic Tests for Colorectal Adenocarcinoma

Sources

Anatomical Context for Colorectal Adenocarcinoma

MalaCards organs/tissues related to Colorectal Adenocarcinoma:

⁴¹

Liver, Colon, Lung, Endothelial, Bone, Kidney, Prostate

Sources

Publications for Colorectal Adenocarcinoma

Articles related to Colorectal Adenocarcinoma:

(show top 50) (show all 627)

#	Title	Authors	Year
1	Histology of colorectal adenocarcinoma with double somatic mismatch repair mutations is indistinguishable from those caused by lynch syndrome. ( 29723603 )	Hemminger J.A....Frankel W.L.	2018
2	SCF/c-KIT Signaling Increased Mucin2 Production by Maintaining Atoh1 Expression in Mucinous Colorectal Adenocarcinoma. ( 29786668 )	Shen P....Zhou D.	2018
3	MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma. ( 29193645 )	RAosAonen K....Stenman J.	2018
4	Collision tumor consisting of a colorectal adenocarcinoma and dissemination of a gastric adenocarcinoma. ( 29326826 )	Miyamoto R....Yamamoto M.	2018
5	Expression of Epidermal Growth Factor Receptor in Colorectal Adenocarcinoma and its Correlation with Clinicopathological Factors. ( 29950257 )	Nemanqani D.M....Al-Sufyani W.M.	2018
6	In vivo identification of novel TGIF2LX target genes in colorectal adenocarcinoma using the cDNA-AFLP method. ( 29960902 )	Mobini G.R....Heidari M.	2018
7	Cellular mechanism of resistance of human colorectal adenocarcinoma cells against apoptosis-induction by Russell's Viper venom l-amino acid oxidase (Rusvinoxidase). ( 29702182 )	Mukherjee A.K....Mackessy S.P.	2018
8	Hepatobiliary and Pancreatic: Hepatic nodules in a patient with familial adenomatous polyposis and colorectal adenocarcinoma. ( 29284077 )	CrimA- F....Pomerri F.	2018
9	Localized lymphoid hyperplasia of the spleen mimicking metastatic colorectal adenocarcinoma. ( 29952067 )	Huynh F....Smith M.	2018
10	MET amplification, expression, and exon 14 mutations in colorectal adenocarcinoma. ( 29641976 )	Zhang M....Du X.	2018
11	Predictors for local recurrence and distant metastasis of mucinous colorectal adenocarcinoma. ( 29361368 )	Emile S.H....Khafagy W.	2018
12	Nuclear expression of claudin-3 in human colorectal adenocarcinoma cell lines and tissues. ( 29285188 )	Tokuhara Y....Hirakawa E.	2018
13	Lysine-specific demethylase 2A expression is associated with cell growth and cyclin D1 expression in colorectal adenocarcinoma. ( 29683067 )	Cao L.L....Wang H.	2018
14	Expression of GAEC1 mRNA and protein and its association with clinical and pathological parameters of patients with colorectal adenocarcinoma. ( 29337242 )	Wahab R....Lam A.K.	2018
15	Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma. ( 29955144 )	Papke D.J....Dong F.	2018
16	Investigating the association between African spontaneously fermented dairy products, faecal carriage of Streptococcus infantarius subsp. infantarius and colorectal adenocarcinoma in Kenya. ( 29079186 )	Kaindi D.W.M....Hattendorf J.	2018
17	Triple primary malignancies in a patient with colorectal adenocarcinoma: A case report. ( 29216528 )	Huang Q....Lian L.	2018
18	Decreased Expression of the Polarity Regulatory PAR Complex Predicts Poor Prognosis of the Patients with Colorectal Adenocarcinoma. ( 29220829 )	Yeo M.K....Kim K.H.	2018
19	High microRNA-28-5p expression in colorectal adenocarcinoma predicts short-term relapse of node-negative patients and poor overall survival of patients with non-metastatic disease. ( 29688883 )	Tsiakanikas P....Scorilas A.	2018
20	Colorectal Adenocarcinoma with an Alternative Serrated Pathway. ( 29805354 )	Eizuka M....Sugai T.	2018
21	Expression and location of IL-17A, E, F and their receptors in colorectal adenocarcinoma: Comparison with benign intestinal disease. ( 29548809 )	Liu Y....Sun Y.	2018
22	The Smad4/PTEN Expression Pattern Predicts Clinical Outcomes in Colorectal Adenocarcinoma. ( 29056035 )	Chung Y....Paik S.S.	2018
23	CT-based Radiomics Signature to Discriminate High-grade From Low-grade Colorectal Adenocarcinoma. ( 29503175 )	Huang X....Liu Z.	2018
24	Long Noncoding RNAs in Colorectal Adenocarcinoma; an in silico Analysis. ( 29948619 )	Ansari H....Asl J.M.	2018
25	Anatomical subsite can modify the association between meat and meat compounds and risk of colorectal adenocarcinoma: findings from three large US cohorts. ( 29873077 )	Etemadi A....Sinha R.	2018
26	p38 inhibitor inhibits the apoptosis of cowanin-treated human colorectal adenocarcinoma cells. ( 29620273 )	Chowchaikong N....Watanapokasin R.	2018
27	Metformin and aspirin treatment could lead to an improved survival rate for Type 2 diabetic patients with stage II and III colorectal adenocarcinoma relative to non-diabetic patients. ( 29456855 )	De Monte A....Bonin S.	2018
28	Ultrastructure of colorectal adenocarcinoma and peritumoral tissue in untreated patients. ( 29419351 )	Osorio H.L....SardiA+as C.E.	2018
29	Intermittent low dose irradiation enhances the effectiveness of radio- and chemo-therapy for human colorectal adenocarcinoma cell line HT-29. ( 28560404 )	Wang Y....Yin D.	2017
30	miRNA biogenesis-associated RNase III nucleases Drosha and Dicer are upregulated in colorectal adenocarcinoma. ( 28943952 )	Kim S....Park J.W.	2017
31	Expression of pattern recognition receptor genes and mortality in patients with colorectal adenocarcinoma. ( 28533893 )	Royse K.E....Jiao L.	2017
32	Clinicopathologic significance of TRAP1 expression in colorectal cancer: a large scale study of human colorectal adenocarcinoma tissues. ( 28088229 )	Pak M.G....Roh M.S.	2017
33	Aurora Kinase A Is a Prognostic Marker in Colorectal Adenocarcinoma. ( 28013532 )	Koh H.M....Maeng Y.H.	2017
34	Late recurrence of colorectal adenocarcinoma as a renal tumour by direct spread via the ureter. ( 28588649 )	DrAoger D.L....Hakenberg O.	2017
35	Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing. ( 27863258 )	Nowak J.A....Dong F.	2017
36	An Unusual Case of Colorectal Adenocarcinoma Presenting as an Anterior Mediastinal Mass. ( 29169975 )	RodrA-guez-LA^pez J.L....VAclez-CortAcs H.A.	2017
37	miR-15a-5p, A Novel Prognostic Biomarker, Predicting Recurrent Colorectal Adenocarcinoma. ( 28405803 )	Kontos C.K....Scorilas A.	2017
38	Doxorubicin-Wrapped Zinc Oxide Nanoclusters for the Therapy of Colorectal Adenocarcinoma. ( 29143771 )	Kim S....Cho H.J.	2017
39	KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior. ( 28188750 )	Jang S....Kim J.W.	2017
40	Two case reports: Colorectal adenocarcinoma in children. ( 29145239 )	Ahn C.H....Kim S.C.	2017
41	Eukaryotic translation initiation factor 4E (eIF-4E) expressions are associated with poor prognosis in colorectal adenocarcinoma. ( 28242042 )	Chen Y.T....Chai C.Y.	2017
42	FGFR2 Amplification in Colorectal Adenocarcinoma. ( 28835367 )	Carter J.H....Duncavage E.J.	2017
43	Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via Wnt/I^-catenin signaling pathway in human colorectal adenocarcinoma. ( 28259923 )	Wang Y.P....Ma S.P.	2017
44	Evaluation of safety, feasibility and the long-term outcomes of colorectomy for colorectal adenocarcinoma in patients older than 80 years of age. ( 29046791 )	Yukawa N....Masuda M.	2017
45	Implications of inflammation and remodeling of the enteric glial cells in colorectal adenocarcinoma. ( 28730232 )	TAcrtea E.A....Sfredel V.	2017
46	Clinical and Histopathologic Features of Colorectal Adenocarcinoma in Crohn's Disease. ( 28654553 )	Galata C....Horisberger K.	2017
47	6-shogaol induces autophagic cell death then triggered apoptosis in colorectal adenocarcinoma HT-29 cells. ( 28641163 )	Li T.Y....Chiang B.H.	2017
48	Hierarchical cluster analysis and chemical characterisation of Myrtus communis L. essential oil from Yemen region and its antimicrobial, antioxidant and anti-colorectal adenocarcinoma properties. ( 28068844 )	Anwar S....Wessjohann L.	2017
49	Human epidermal growth factor (Her-2) in gastric and colorectal adenocarcinoma. ( 28770892 )	Shabbir A....Khalid A.B.	2017
50	Survival benefits in colorectal adenocarcinoma with the use of metformin among a black diabetic inner city population. ( 29308089 )	Zhu R.C....Vignesh S.	2017

Sources

Genes for Colorectal Adenocarcinoma

Genes related to Colorectal Adenocarcinoma (0 elite genes):

(show all 23)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	FABP6	Fatty Acid Binding Protein 6	Protein Coding	29.8	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Functions (show sections)
2	AURKA	Aurora Kinase A	Protein Coding	28.01	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Variants (show sections)
3	FGFBP1	Fibroblast Growth Factor Binding Protein 1	Protein Coding	26.17	GeneCards inferred via : Publications Summaries (show sections)
4	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	25.85	GeneCards inferred via : Publications Variants (show sections)
5	TP53	Tumor Protein P53	Protein Coding	24.16	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	KRT7	Keratin 7	Protein Coding	23.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	CDX2	Caudal Type Homeobox 2	Protein Coding	23.82	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	23.79	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	MLH1	MutL Homolog 1	Protein Coding	22.95	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	KRT20	Keratin 20	Protein Coding	22.94	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	22.91	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	MUC2	Mucin 2, Oligomeric Mucus/Gel-Forming	Protein Coding	22.72	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	CDH1	Cadherin 1	Protein Coding	22.58	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	EGFR	Epidermal Growth Factor Receptor	Protein Coding	22.39	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	CTNNB1	Catenin Beta 1	Protein Coding	22.35	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	MSH2	MutS Homolog 2	Protein Coding	22.19	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	PIM2	Pim-2 Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	15.77	GeneCards inferred via : Functions Expressions (show sections)
18	CDK8	Cyclin Dependent Kinase 8	Protein Coding	14.55	GeneCards inferred via : Publications Variants (show sections)
19	CEACAM5	Carcinoembryonic Antigen Related Cell Adhesion Molecule 5	Protein Coding	13.81	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	C2orf68	Chromosome 2 Open Reading Frame 68	Protein Coding	12.77	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	11.98	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
22	MSH6	MutS Homolog 6	Protein Coding	11.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
23	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	11.89	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Colorectal Adenocarcinoma

Sources

Expression for Colorectal Adenocarcinoma

Search GEO for disease gene expression data for Colorectal Adenocarcinoma.

Sources

Pathways for Colorectal Adenocarcinoma

Pathways related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 60)

#	Super pathways	Score	Top Affiliating Genes
1	Developmental Biology ⁶⁶ Show member pathways Axon guidance ⁶⁶	13.52	BRAF CDK8 CTNNB1 EGFR HRAS KRAS
2	fMLP Pathway ⁶⁴ Show member pathways Alpha-Adrenergic Signaling ⁶⁴ CCR3 Pathway in Eosinophils ⁶⁴ CXCR4 Pathway ⁶⁴ Huntington's Disease Pathway ⁶⁴ Internalin Pathway ⁶⁴ Signal transduction Activation of PKC via G-Protein coupled receptor ²² VEGF and S-1P Signaling ⁶⁴	12.98	BRAF CDH1 CDX2 CTNNB1 HRAS KRAS
3	MAPK signaling pathway ¹ ³⁷	12.77	BRAF EGFR HRAS KRAS TP53
4	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.77	BRAF CDH1 CTNNB1 EGFR HRAS KRAS
5	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.74	BRAF CDH1 EGFR HRAS KRAS TP53
6	Ras signaling pathway ³⁷ Show member pathways Rap1 signaling pathway ³⁷	12.69	BRAF CDH1 CTNNB1 EGFR HRAS KRAS
7	4-1BB Pathway ⁶⁴ Show member pathways CD27 Pathway ⁶⁴ CD40 Signaling ⁶⁴ CMV and MAPK Pathways ⁶⁴ NF-KappaB Activation by EBV ⁶⁴ NF-kappaB Activation by Viruses ⁶⁴ PKR Pathway ⁶⁴ SUMO Pathway ⁶⁴ TNFR2 Pathway ⁶⁴	12.68	BRAF EGFR HRAS KRAS TP53
8	Pathways in cancer ³⁷	12.68	BRAF CDH1 CTNNB1 EGFR HRAS KRAS
9	Development HGF signaling pathway ²² Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development Neurotrophin family signaling ²² MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ Neurotrophin signaling pathway ³⁷ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.67	BRAF CDH1 CTNNB1 HRAS KRAS TP53
10	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²² Rac1/Pak1/p38/MMP-2 pathway ¹	12.55	CTNNB1 EGFR HRAS KRAS MSH2 TP53
11	DNA Damage ⁴	12.52	AURKA CDK8 MLH1 MSH2 TP53
12	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.52	BRAF CDH1 CDX2 CTNNB1 EGFR HRAS
13	mTOR signaling pathway (KEGG) ⁶⁵ Show member pathways mTOR signaling pathway ³⁷	12.51	BRAF EGFR HRAS KRAS TP53
14	ErbB signaling pathway ¹ ³⁷ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶¹ Renal cell carcinoma ³⁷ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.48	BRAF EGFR HRAS KRAS TP53
15	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ¹	12.46	BRAF CDH1 CTNNB1 EGFR HRAS KRAS
16	HTLV-I infection ³⁷	12.43	CTNNB1 HRAS KRAS TP53
17	Arrhythmogenic right ventricular cardiomyopathy (ARVC) ³⁷ Show member pathways Arrhythmogenic Right Ventricular Cardiomyopathy ¹ Calpain Protease Regulates Cellular Mechanics ⁶⁴	12.43	CTNNB1 EGFR HRAS KRAS
18	Apoptosis Pathway ⁷² Show member pathways Akt Pathway ⁷² NF-kappaB Pathway ⁷²	12.43	CTNNB1 EGFR HRAS KRAS TP53
19	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.4	BRAF CTNNB1 HRAS KRAS
20	Signaling by FGFR2 ⁶⁶ Show member pathways FGFR2 ligand binding and activation ⁶⁶ FGFR2b ligand binding and activation ⁶⁶ Signaling by FGFR ⁶⁶	12.28	BRAF FGFBP1 HRAS KRAS
21	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ¹	12.28	BRAF CDH1 CTNNB1 HRAS
22	Proteoglycans in cancer ³⁷	12.24	BRAF CTNNB1 EGFR HRAS KRAS TP53
23	G-protein signaling Ras family GTPases in kinase cascades (scheme) ²² Show member pathways Activation of the AP-1 family of transcription factors ⁶⁶ Immune response Oncostatin M signaling via MAPK in human cells ²² MAPK Cascade ¹ Oncostatin M Signaling Pathway ¹	12.23	BRAF HRAS KRAS TP53
24	mTOR Pathway ⁷² Show member pathways Insulin Pathway ⁷² TGF-beta Pathway ⁷²	12.19	BRAF HRAS KRAS TP53
25	AKT Signaling Pathway ⁶⁷	12.16	EGFR HRAS KRAS TP53
26	NGF Pathway ⁶⁴ Show member pathways TRKA Signaling ⁶⁴	12.16	BRAF HRAS KRAS TP53
27	EGF/EGFR Signaling Pathway ¹	12.14	AURKA BRAF EGFR HRAS KRAS
28	FoxO signaling pathway ³⁷ Show member pathways PLK2 and PLK4 events ¹ Polo-like kinase signaling events in the cell cycle ¹	12.1	BRAF EGFR HRAS KRAS
29	Direct p53 effectors ¹	12.08	EGFR MLH1 MSH2 TP53
30	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.07	BRAF EGFR KRAS
31	G12-G13 in Cellular Signaling ⁶⁴	12.03	CDH1 CTNNB1 HRAS KRAS
32	Hepatitis C ³⁷	12.03	BRAF EGFR HRAS KRAS TP53
33	Thyroid hormone signaling pathway ³⁷	11.99	CTNNB1 HRAS KRAS TP53
34	DNA Damage Response (only ATM dependent) ¹	11.98	CTNNB1 HRAS KRAS TP53
35	Glioblastoma Multiforme ⁶⁴	11.93	BRAF CTNNB1 EGFR HRAS KRAS TP53
36	Gap junction ³⁷	11.84	EGFR HRAS KRAS
37	VEGF Pathway (Tocris) ⁷² Show member pathways Sorafenib Pharmacodynamics ⁶¹	11.81	BRAF HRAS KRAS
38	Colorectal Cancer Metastasis ⁶⁴	11.78	BRAF CDH1 CTNNB1 EGFR KRAS MLH1
39	Platinum drug resistance ³⁷	11.75	MLH1 MSH2 TP53
40	Adherens junction ³⁷	11.74	CDH1 CTNNB1 EGFR
41	Bladder cancer ³⁷ ¹	11.71	BRAF CDH1 EGFR HRAS KRAS TP53
42	Mitophagy - animal ³⁷	11.69	HRAS KRAS TP53
43	Negative regulation of MAPK pathway ⁶⁶ Show member pathways RAF activation ⁶⁶	11.69	BRAF HRAS KRAS
44	Central carbon metabolism in cancer ³⁷	11.66	EGFR HRAS KRAS TP53
45	Long-term depression ³⁷	11.65	BRAF HRAS KRAS
46	Agrin Interactions at Neuromuscular Junction ⁶⁴	11.61	EGFR HRAS KRAS
47	Aryl Hydrocarbon Receptor ¹	11.54	EGFR HRAS KRAS
48	Doxorubicin Pathway, Pharmacokinetics ⁶¹ Show member pathways Doxorubicin Pathway (Cancer Cell), Pharmacodynamics ⁶¹	11.45	MLH1 MSH2 TP53
49	Stabilization and expansion of the E-cadherin adherens junction ¹	11.44	CDH1 CTNNB1 EGFR
50	Vemurafenib Pathway, Pharmacodynamics ⁶¹	11.42	BRAF EGFR HRAS KRAS

Sources

GO Terms for Colorectal Adenocarcinoma

Cellular components related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	flotillin complex	GO:0016600	8.62	CDH1 CTNNB1

Biological processes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 22)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	9.92	BRAF CTNNB1 HRAS KRAS TP53
2	cell proliferation	GO:0008283	9.91	CTNNB1 EGFR HRAS PIM2 TP53
3	positive regulation of transcription, DNA-templated	GO:0045893	9.91	CDH1 CDX2 CTNNB1 EGFR PIM2 TP53
4	negative regulation of apoptotic process	GO:0043066	9.88	AURKA BRAF CEACAM5 EGFR PIM2 TP53
5	Ras protein signal transduction	GO:0007265	9.77	HRAS KRAS TP53
6	cellular response to drug	GO:0035690	9.75	BRAF EGFR TP53
7	positive regulation of MAP kinase activity	GO:0043406	9.73	EGFR HRAS KRAS
8	positive regulation of cell proliferation	GO:0008284	9.73	CDX2 CTNNB1 EGFR FGFBP1 HRAS KRAS
9	epidermal growth factor receptor signaling pathway	GO:0007173	9.72	EGFR HRAS KRAS
10	negative regulation of neuron apoptotic process	GO:0043524	9.67	BRAF HRAS KRAS MSH2
11	determination of adult lifespan	GO:0008340	9.61	MSH2 TP53
12	entry of bacterium into host cell	GO:0035635	9.6	CDH1 CTNNB1
13	positive regulation of isotype switching to IgG isotypes	GO:0048304	9.58	MLH1 MSH2
14	positive regulation of fibroblast growth factor receptor signaling pathway	GO:0045743	9.57	CTNNB1 FGFBP1
15	response to isolation stress	GO:0035900	9.54	HRAS KRAS
16	ERBB2 signaling pathway	GO:0038128	9.5	EGFR HRAS KRAS
17	cellular response to indole-3-methanol	GO:0071681	9.49	CDH1 CTNNB1
18	positive regulation of isotype switching to IgA isotypes	GO:0048298	9.48	MLH1 MSH2
19	somatic recombination of immunoglobulin gene segments	GO:0016447	9.46	MLH1 MSH2
20	negative regulation of cell proliferation	GO:0008285	9.43	CTNNB1 FABP6 FGFBP1 HRAS PIM2 TP53
21	somatic recombination of immunoglobulin genes involved in immune response	GO:0002204	9.16	MLH1 MSH2
22	anterior/posterior axis specification	GO:0009948	8.8	AURKA CDX2 CTNNB1

Molecular functions related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein heterodimerization activity	GO:0046982	9.83	AURKA BRAF CTNNB1 EGFR TP53
2	protein kinase activity	GO:0004672	9.8	AURKA BRAF CDK8 EGFR PIM2
3	ATP binding	GO:0005524	9.76	AURKA BRAF CDK8 EGFR MLH1 MSH2
4	protein kinase binding	GO:0019901	9.65	AURKA CTNNB1 EGFR MSH2 TP53
5	protein phosphatase binding	GO:0019903	9.5	CTNNB1 EGFR TP53
6	mismatched DNA binding	GO:0030983	9.37	MLH1 MSH2
7	nucleotide binding	GO:0000166	9.1	AURKA BRAF EGFR HRAS KRAS PIM2
8	guanine/thymine mispair binding	GO:0032137	8.96	MLH1 MSH2

Sources

Sources for Colorectal Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia